相关实验视频
Updated: Jun 9, 2025

06:00
Fixation and Operational Method for Abdominal Massage in T2DM Mice
Published on: March 7, 2025
150
孕期糖尿病中的甲福明:生理作用和临床应用
Taitum Mason1, Simon Alesi1, Melinda Fernando1
1Monash Centre for Health Research and Implementation (MCHRI), Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Melbourne, Australia.
Nature reviews. Endocrinology
|October 25, 2024
概括
孕期糖尿病 (GDM) 在怀孕期间使用甲胺显示了诸如减肥和新生儿并发症等益处. 然而,研究数据不一致,使其对高血糖的整体疗效不清楚,需要进一步的子组分析.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 孕产妇和胎儿医学 孕产妇和胎儿医学
背景情况:
- 甲胺是一种常见的口服低血糖药物,用于治疗2型糖尿病.
- 由于安全性和疗效方面的担忧,其在怀孕期间用于妊娠糖尿病 (GDM) 的使用受到争议.
研究的目的:
- 审查甲福明的代谢功能和现有的关于其在怀孕期间用于GDM的文献.
- 确定关于甲福明在患有GDM的孕妇的安全性和有效性的知识差距.
主要方法:
- 综合性文献综述和现有研究的综合.
- 在GDM怀孕中分析甲福明对各种孕产妇和新生儿结局的影响.
主要成果:
- 在GDM中使用甲福明与减少妊娠期体重增加,新生儿低血糖症和宏观症有关.
- 甲福明会增加孕妇GDM的胰岛素敏感性.
- 研究和元分析中的异质性导致对甲福明在GDM中高血糖症疗效的相互矛盾的发现.
结论:
- 需要使用创新的分析方法进行进一步的研究,根据个体特征和治疗方案进行分层.
- 确定在怀孕期间可能受益于甲福明的GDM妇女的特定子组至关重要.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
176
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
176
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Pathophysiology of Diabetes
874
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
874
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
161
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
161
Oral Hypoglycemic Agents: Glinides
142
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
142
Hypoglycemia and Glucagon
153
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
153

